Tesla has been one of the most successful and most debated publicly-traded companies, It’s a brand that has a devoted following that also has plenty of skeptics. In its most-recent quarter, however, the company continued to deliver strong numbers despite a very challenging operating environment. The question -- and it’s a big one -- is how big can the company become? That answer may lie in whether you believe Tesla is a car company or a tech company. Anirban Mahanti has your answers and he joins 7invesitng Now to explain. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

The cannabis space has been a challenging area for investors. It seems like an area full of opportunity -- and in some ways it has been -- but it has been a market that has proven a tough one for companies to stand out in. Yes, there are a lot of players trying to make an impact but cannabis itself is a commodity and building brands that resonate with consumers has not been easy. A pioneer in the field, Morgan Paxhia has been investing in the cannabis space for as long as anyone,. He serves as one of the founders of Poseidon Investment Management, one of the longest-running dedicated cannabis investment funds in the world. In a market where few investors have consistently made money, Paxhia and his company have been successful when it comes to identifying winners in the cannabis space. Morgan started Poseidon with his sister Emily way back in 2013. The sibling duo believed that the market for legal cannabis as an investable space began when Colorado legalized marijuana for recreational use. That happened back in 2012 and Poseidon was formed not long after. Since then, Morgan and Emily have been on the cutting edge of investing in this emerging, challenging space. A first-of-its-kind company, Poseidon made its first investments in the cannabis space in 2014. The company has a number of funds and even has an ETF that’s on the way giving it deep exposure to what Paxhia considers a market that’s still in its very early days. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Simon Erickson has spent the past few days attending the Wall Street Journal’s annual technology conference. He takes a break from the show to update us on three big stories he’s following from the conference -- ViacomCBS CEO Bob Bakish on the streaming landscape, Reddit CEO Steve Huffman on the company’s role in facilitating discussion that has impacted the stock market, and Creative Arts Agency Co-Chair Richard Lovett on Hollywood’s power shift. He’ll also give us an overview of what’s happening at the conference and share any surprises that happened on day three of the big event. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Investors often see synthetic biology referred to as an industry, but that's not quite accurate. Biology touches many different industries ranging from food to chemicals, energy to health care. In the future, biological systems will be used for economic activities not typically associated with living things, such as digital data storage, manufacturing metallic nanoparticles, robotics, and perhaps even semiconductors and computing. 7investing Lead Advisor Maxx Chatsko has always defined synthetic biology as a way of thinking. It's about applying an engineering mindset to biology. After all, the primary goal of synthetic biology is to precisely engineer living things and achieve a predictable, reproducible outcome. These outcomes are unbounded by economic constructs such as sectors and industries or goods and services. Semantics and linguistics aside, there are foundational questions that need to be asked before synthetic biology can live up to its potential. How can scientists precisely engineer living things and observe a reproducible outcome? What foundational tools and technology layers are needed to enable synthetic biology? If these critical pieces of infrastructure don't exist, then who or what should be tasked with building them? Andrew Hessel is often the one doing the asking. Increasingly, he's been doing a lot of the answering, too. Hessel is hands down the best blue-sky thinker in synthetic biology. He completed his undergraduate (cellular, molecular, and microbial biology) and graduate (bacterial genomics) work at the University of Calgary. He's been fascinated with the amazing potential to program biology ever since starting his career as a scientist at Amgen over two decades ago. More recently, Hessel served on the faculty at Singularity University, led the synthetic biology division at Autodesk, founded Humane Genomics to engineer oncolytic viruses for personalized cancer treatments, and co-founded the Genome-Project-Write Project. The infamous Human Genome Project was concerned with developing the tools required to sequence (or read) a full human genome, whereas GP-write is concerned with developing the tools required to synthesize (or write) full genomes of various organisms. Why stop there? In early 2022, Hessel and bestselling science writer Amy Webb will publish a book called "The Genesis Machine: Our Quest to Rewrite Life in the Age of Synthetic Biology" describing how we got here and where we might be headed. In this episode of the podcast, Maxx Chatsko and Andrew Hessel discuss what he's been up to lately, what he's most excited about in synthetic biology, and what's ahead for programmable biology. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Every company -- even our favorite investments -- have things that concern us. In most cases, these are just little things that we keep an eye on. There are times, however, when we do our research on a company only to discover something so egregious that we simply don’t want to invest. These “red flags” stop us in our tracks and cause us to move on from that particular investment. What constitutes a red flag, however, differs from investor to investor. We’ll take a look at some of ours and share some that you shared with us. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

Given the rise of exciting new therapeutic modalities ranging from mRNA to gene editing, investors would be forgiven for overlooking opportunities in medical devices. They might be worth a closer look though. In this episode of the 7investing podcast, the team's health-care trio provide a high-level overview of the regulatory environment for medical devices, describe why and how genetic tests are regulated as medical devices, and provide three examples of companies in the space and how they fit within the regulatory landscape. Medical devices are regulated by the U.S. Food and Drug Administration (FDA) within three categories: Class I devices are the simplest and least likely to pose safety risks. Examples include bedpans or medical gauze. These require regulatory clearance. Class II devices are more complicated and require more data within their regulatory submissions to ensure the safety and effectiveness of the device. Examples include X-ray machines or knee braces. These require regulatory clearance. Class III devices are the most complicated and pose the greatest potential risk to patients, such as life-supporting, life-sustaining, or implantable devices. Examples include liquid biopsies, pacemakers, or implantable contact lenses. These require regulatory approval. Although Class I and Class II medical devices can be submitted through the 510(k) process and only need to show equivalence to a predicate ("existing") device, Class III medical devices must be submitted through the more rigorous premarket approval (PMA) process that often requires a clinical trial. Unlike a drug candidate that requires at least three separate clinical trials (phase 1, phase 2, and phase 3), a Class III medical device often only requires a single clinical trial. It seems odd, but genetic tests and liquid biopsies are also regulated as medical devices. These product candidates are categorized into one of the classes above, which typically impacts how and where they can be used. The three designations of genetic tests include: Research use only (RUO) products cannot be used as diagnostics and don't require a regulatory submission. RUOs can form the basis of a more advanced diagnostic product from the originator or its customers. These serve an important role, but generally have the smallest market opportunity. Laboratory developed tests (LDT) must be designed, manufactured, and processed by a single CLIA-certified laboratory. These tend to be Class II medical devices and require a 510(k) filing. LDTs are often used with centralized business models, where patient samples are shipped to a centralized facility. Examples include genetic screening tests. These have the largest volume potential, but low to moderate pricing and insurance coverage. These have moderate to large market opportunities. In vitro diagnostics (IVD) are more robust tests and can be shipped to the point of care, which means placed in the hands of doctors, oncologists, and medical facilities. Because these are not self-contained within CLIA-certified labs, they're often classified as Class III medical devices and require a PMA filing and clinical trial. IVDs are often used with distributed business models, where patient samples are processed at the point of care. Examples include liquid biopsies. These have both large volume and high price potential, which results in the largest market opportunities by monetary value. Finally, the podcast concludes with three different examples of medical device companies: 7investing Lead Advisor Dana Abramovitz discusses Inviate (NYSE: NVTA). 7investing Lead Advisor Maxx Chatsko discusses Nano-X Imaging (NASDAQ: NNOX). 7investing Lead Advisor Simon Erickson discusses STAAR Surgical (NASDAQ: STAA)

Investors hear a lot about genomics these days, but what does it all mean, exactly? 7investing Lead Advisors Simon Erickson and Maxx Chatsko team up to discuss what investors should look for in pre-commercial drug developers. To provide practical examples, they discuss how continuous improvements in DNA sequencing have created various technological offshoots now loosely called "genomics," including exciting new opportunities in precision oncology and liquid biopsies. Finally, they provide a high-level overview of DNA editing tools and approaches, including base editing and prime editing. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

America's health care bill may cost us $4 trillion a year. But at least we're getting more efficient. Technological advances are improving several of health care's most serious issues. Oncology diagnostics are now able to detect earlier-stage cancers before patients even begin showing symptoms. Remote monitoring is taking vital signs of the elderly without them ever needing to step into a hospital. The COVID vaccine is renewing our focus on mRNA, genomic sequencing is unlocking personalized treatments, and spatial biology is quickly capturing the full attention of the medical community. But due to heavy regulations and the specialized nature of the work, isn't the health care industry also notoriously slow to embrace innovation? Will these exciting new technology improvements actually pay off for forward-thinking investors? To help us answer those questions, we've brought in a health care expert. Nina Deka is a senior analyst for ROBO Global, where she contributes to the firm's health care technology index that carries the ticker "HTEC". Nina has spent her career either working in or covering the health care industry, and she is well-versed in the ways of how technology can improve it. In an exclusive interview, Nina spoke with 7investing CEO Simon Erickson about several of health care's most important developing trends and the specific companies that investors might consider as opportunities. Publicly-traded companies mentioned in this interview include Akoya Biosciences, Exact Sciences, Illumina, Invitae, Moderna, Pacific Biosciences of California, Teladoc, and Vocera Communications. 7investing's advisors or its guests may have positions in the companies mentioned. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

There are a lot of exciting new frontiers hitting the headlines of today's financial media. 7investing lead advisors Steve Symington and Simon Erickson are joined by CryptoEQ founder Spencer Randall to break down the most important things to watch for as investors.  Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing

It’s beginning to look a lot like Christmas at least as far as many retailers are concerned. The holiday season has crept into October so some players are offering Black Friday-like deals before Halloween has even passed. It’s also going to be an interesting year with “supply chain” being both a real problem and a ready excuse. Dan Kline looks at how investors should view the season on the episode of 7investing Now. Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year. Start your journey toward's financial independence: https://www.7investing.com/subscribe Stop by our website to level-up your investing education:  https://www.7investing.com Follow us: ► https://www.facebook.com/7investing ► https://twitter.com/7investing ► https://instagram.com/7investing